Trial Profile
Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Mylan
- 04 Oct 2023 Results of pooled analysis (from studies NCT02469987 and NCT04633564) to establish a population pharmacokinetic model assessing to assess pharmacokinetic linearity of MYL-1402O and Avastin across dose ranges in patients with non-squamous non-small cell lung cancer published in the European Journal of Drug Metabolism and Pharmacokinetics
- 28 Sep 2022 According to Celltrion media release, the USFDA has approved Vegzelma, for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer ; recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer based on totality of evidence, including this pivotal trial
- 10 Mar 2022 This trial has been discontinued in Italy.